Almhanna, Khaldoun
Miron, Maria Luisa Limon
Wright, David
Gracian, Antonio Cubillo
Hubner, Richard A.
Van Laethem, Jean-Luc
López, Carolina Muriel
Alsina, Maria
Muñoz, Frederico Longo
Bendell, Johanna
Firdaus, Irfan
Messersmith, Wells
Ye, Zhan
Fasanmade, Adedigbo A.
Danaee, Hadi
Kalebic, Thea
Funding for this research was provided by:
Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 10 January 2017
Accepted: 30 January 2017
First Online: 11 February 2017
Compliance with ethical standards
:
: Disclosures are as follows. Khaldoun Almhanna: Lilly advisor/board member, Genentech speaker’s bureau. Richard A. Hubner: Eli Lilly advisory board member. Wells Messersmith: Research support from Millennium. Zhan Ye, Adedigbo A. Fasanmade, Hadi Danaee and Thea Kalebic: full-time employees of Millennium. Maria Luisa Limon Miron, David Wright, Antonio Cubillo Gracian, Jean-Luc Van Laethem, Carolina Muriel López, Maria Alsina, Frederico Longo Muñoz, Johanna Bendell, and Irfan Firdaus: nothing to disclose.
: This study was conducted according to the principles set out in the Declaration of Helsinki, in compliance with International Conference on Harmonisation, Good Clinical Practice guidelines, and local regulatory requirements. Institutional review boards/ethics committees at the participating investigational centers approved the study.
: Written informed consent was obtained from all individual patients included in the study.
: This study was funded by Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.